Leadiant Biosciences Ltd. is focused on the discovery of molecules and therapies to help improve the lives of people around the world who suffer from specific diseases.

The study of rare diseases is an integral part of Leadiant Biosciences’ research activity and heritage in rare diseases dating back to 1984, we have been among the first four Companies in the world to receive an Orphan Drug Designation in the United States. Since then we have obtained several others.

We continue to honor this legacy with our commitment to patients by advancing a diverse pipeline of new drug and therapeutic candidates. Our innovative research programs and development of novel product candidates are led by our scientists in partnership with a wide range of physicians, researchers and leading academic and biotechnology organizations as well as with a close dialogues with the Health Authorities around the world.

Brand Name (active ingredient) Disease Area/Indication Stage of Development
Chenodeoxycholic Acid (CDCA)(LB101) Cerebrotendinous Xanthomatosis (CTX)/Metabolic Phase III (US)
Cysteamine hydrochoride (LB201) Cystinosis (corneal cysteine deposit)/Lysosomal storage disease New Formulation
Cysteamine hydrochoride (LB202) Cystinosis (corneal cysteine deposit)/Lysosomal storage disease New Delivery System
N-acetyl-D- mannosamine (LB301) GNE Myopathy/Myopathy Phase III
N-acetyl-D- mannosamine (LB701) Nephrology Phase I
Roneparstat (LB401) Hematological Malignancies/Oncology Phase II
STP-206 Necrotizing Enterocolitis/Neonatology Phase I
Amphotericin B Lipid Complex (LB501) Mycotic keratitis/Infectious Disease Pre-Clinical
Elapegademase (LB601) Scleroderma/Immunology-Autoimmune Diseases Pre-Clinical